Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.68 |
| ▸ | FLT3 | P36888 | 16/20 | 0.68 |
| ▸ | JAK1 | P23458 | 4/20 | 0.68 |
| ▸ | JAK3 | P52333 | 4/20 | 0.68 |
| ▸ | TYK2 | P29597 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CDK4 | P11802 | 1/20 | 0.66 |
| ▸ | FLT1 | P17948 | 1/20 | 0.66 |
| ▸ | CCND3 | P30281 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | FLT4 | P35916 | 1/20 | 0.66 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24664561 | 0.99 | JAK2 (0.67) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664354 | 0.98 | JAK2 (0.69) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664356 | 0.95 | JAK2 (0.68) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664447 | 0.93 | JAK2 (0.67) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664562 | 0.93 | JAK2 (0.68) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24663796 | 0.91 | JAK2 (0.66) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664499 | 0.90 | JAK2 (0.65) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL22852546 | 0.89 | JAK2 (0.65) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664521 | 0.87 | JAK2 (0.65) | JAK2FLT3JAK1JAK3TYK2 | |
| SCHEMBL24664504 | 0.87 | JAK2 (0.59) | JAK2FLT3JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298140-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | JAK2, FLT3, JAK1 | JAK2 1/4885FLT3 2/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.